# Outset Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/outset-medical

- Industry: Medical Devices & Equipment
- Headquarters: San Jose, US
- Website: www.outsetmedical.com
- Total disclosed funding: $443M
- Latest round: Series E (Jan 27, 2020)
- Investors on record: 10

## About

Outset Medical, Inc. is a US-based medical technology firm specializing in innovative dialysis solutions designed to enhance patient care and optimize treatment processes across various healthcare settings.Founded in 2010 and headquartered in San Jose, California, Outset Medical, Inc. focuses on developing advanced hemodialysis systems. The company has successfully raised a total of USD 212.00 mn through various funding rounds, with the most recent being a Private Placement/Follow on amounting to USD 212.00 mn in December 2020. The company has completed 11 deals, with a notable IPO in September 2020 raising USD 241.679 mn. The CEO is Leslie Trigg, and the founder is Islam Gamiel.Outset Medical, Inc. primarily offers the Tablo® Hemodialysis System and TabloCart™, providing a comprehensive solution for dialysis management in diverse healthcare environments, including ICUs and home settings. The Tablo system automates critical dialysis processes, allowing for quicker training and a broader range of treatment options, including Intermittent Hemodialysis and Prolonged Intermittent Renal Replacement Therapy, without being indicated for continuous renal replacement therapy.In 2024, Outset Medical, Inc. reported a revenue of USD 113.69 mn, with an EBITDA of USD -107.65 mn, derived mainly from the sales and servicing of the Tablo Hemodialysis System to healthcare providers and institutions.Outset Medical, Inc. plans to leverage recent funding to enhance its product offerings and expand its market reach. The company is focused on developing new features for the Tablo system and aims to enter additional international markets by 2024. The capital raised will facilitate research and development initiatives as well as support potential expansion efforts into regions currently not served by their products.

## Funding rounds

- Series E, Jan 27, 2020, $115M — T Rowe Price, Fidelity Investments, Partner Fund Management, Perceptive Advisors, D1 Capital Partners
- Series D, Aug 20, 2018, $132M — T Rowe Price, Warburg Pincus, Mubadala Investment Company, Fidelity Investments, Baxter Ventures, Partner Fund Management, Perceptive Advisors
- Series C, May 3, 2017, $77M — T Rowe Price, Warburg Pincus, Vertical Group, Fidelity Investments, Partner Fund Management, Perceptive Advisors
- Series B, Jun 9, 2015, $51M — Warburg Pincus, CRG, Vertical Group, Fidelity Investments, Partner Fund Management, Perceptive Advisors
- Series B, May 5, 2015, $60M — Warburg Pincus, Vertical Group
- Series A, Jun 17, 2010, $4.5M — Warburg Pincus, Vertical Group
- Series A, Feb 26, 2010, $4.5M — Warburg Pincus, Vertical Group

## Investors

- Warburg Pincus (https://capitalatlas.ai/funds/warburg-pincus) — Series A, Series B, Series C, Series D
- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Series A, Series B, Series C
- CRG — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B, Series C, Series D, Series E
- Partner Fund Management — Series B, Series C, Series D, Series E
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C, Series D, Series E
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C, Series D, Series E
- Mubadala Investment Company — Series D
- Baxter Ventures (https://capitalatlas.ai/funds/baxter-ventures) — Series D
- D1 Capital Partners (https://capitalatlas.ai/funds/d1-capital-partners) — Series E